利福平在接受芦可替尼治疗的原发性骨髓纤维化患者中用于治疗播散性结核病。 - Suppr

Suppr

超能文献

Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib.

作者信息

Branco Benoit, Metsu David, Dutertre Marine, Marchou Bruno, Delobel Pierre, Recher Christian, Martin-Blondel Guillaume

机构信息

Department of Hematology, Cancer University Institute of Toulouse Oncopole, Toulouse, France.

Laboratory of Pharmacokinetics and Toxicology, Toulouse University Hospital, Toulouse, France.

出版信息

Ann Hematol. 2016 Jun;95(7):1207-9. doi: 10.1007/s00277-016-2684-0. Epub 2016 Apr 26.

DOI:10.1007/s00277-016-2684-0

PMID:27113251

Abstract

摘要

相似文献

Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib.

Ann Hematol. 2016 Jun;95(7):1207-9. doi: 10.1007/s00277-016-2684-0. Epub 2016 Apr 26.

Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review.

Intern Med. 2022 Apr 15;61(8):1271-1278. doi: 10.2169/internalmedicine.6436-20. Epub 2021 Sep 25.

Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature.

Intern Med. 2018 May 1;57(9):1297-1300. doi: 10.2169/internalmedicine.9165-17. Epub 2017 Dec 27.

Myelofibrosis: An unusual presentation of disseminated tuberculosis.

Int J Mycobacteriol. 2020 Apr-Jun;9(2):216-219. doi: 10.4103/ijmy.ijmy_4_20.

Ruxolitinib and tuberculosis: A case report with brief review.

Indian J Tuberc. 2022 Jul;69(3):354-358. doi: 10.1016/j.ijtb.2021.06.003. Epub 2021 Jun 26.

Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis.

Ann Hematol. 2017 Apr;96(4):697-699. doi: 10.1007/s00277-017-2938-5. Epub 2017 Feb 14.

[Case of chronic kidney failure with thrombotic thrombocytopenic purpura due to miliary tuberculosis].

Nihon Naika Gakkai Zasshi. 1998 Feb 10;87(2):335-7.

Intermittent chemotherapy for miliary tuberculosis in children.

Turk J Pediatr. 1999 Jan-Mar;41(1):53-9.

Two cases of myelofibrosis with severe thrombocytopenia and symptomatology successfully treated with combination of pomalidomide and ruxolitinib.

Leuk Lymphoma. 2015 Feb;56(2):524-6. doi: 10.3109/10428194.2014.924121. Epub 2014 Jul 15.

A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).

Leuk Res. 2020 Jan;88:106272. doi: 10.1016/j.leukres.2019.106272. Epub 2019 Nov 16.

引用本文的文献

Miliary TB and COVID-19 Coinfection in a Patient With a History of Post-polycythemia Vera Myelofibrosis Treated With Ruxolitinib: A Case Report.

Cureus. 2024 Jul 3;16(7):e63791. doi: 10.7759/cureus.63791. eCollection 2024 Jul.

Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review.

Intern Med. 2022 Apr 15;61(8):1271-1278. doi: 10.2169/internalmedicine.6436-20. Epub 2021 Sep 25.

Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data.

Ther Adv Drug Saf. 2021 Aug 26;12:20420986211041277. doi: 10.1177/20420986211041277. eCollection 2021.

Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations.

Cancers (Basel). 2020 Oct 26;12(11):3132. doi: 10.3390/cancers12113132.

Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review.

Infect Drug Resist. 2020 Sep 28;13:3309-3316. doi: 10.2147/IDR.S267997. eCollection 2020.

Necessity to screen and treat latent tuberculosis before ruxolitinib treatment-Ruxolitinib-associated disseminated tuberculosis: A case report and literature review.

IDCases. 2020 Jun 26;21:e00892. doi: 10.1016/j.idcr.2020.e00892. eCollection 2020.

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.

Infect Drug Resist. 2020 Apr 8;13:1017-1021. doi: 10.2147/IDR.S249030. eCollection 2020.

Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis.

Leuk Lymphoma. 2020 Mar;61(3):660-667. doi: 10.1080/10428194.2019.1688323. Epub 2019 Nov 12.

Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

Leukemia. 2019 Apr;33(4):844-862. doi: 10.1038/s41375-019-0388-x. Epub 2019 Jan 30.

Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature.

Intern Med. 2018 May 1;57(9):1297-1300. doi: 10.2169/internalmedicine.9165-17. Epub 2017 Dec 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验